The Role of Purine Metabolism-Related Genes PPAT and IMPDH1 in the Carcinogenesis of Intrahepatic Cholangiocarcinoma Based on Metabonomic and Bioinformatic Analyses

In this study, we investigated the role of tumor microenvironment and serum differential metabolites in intrahepatic cholangiocarcinoma (ICC) carcinogenesis, providing new evidence for ICC treatment. Serum samples from healthy individuals and ICC patients were collected for metabolomic analysis. The purine metabolites such as inosine, guanosine, hypoxanthine, and xanthine were increased in patient serum. TCGA database samples were collected, and the correlation between purine metabolism-related genes and ICC clinical features was analyzed using R language to obtain the differential genes including PPAT, PFAS, ATIC, and IMPDH2. High PPAT expression was associated with poor ICC prognosis. A PPAT silencing model in HCCC-9810 cells was constructed. The cell phenotype was examined by qRT-PCR, CCK-8, transwell, and flow cytometry, showing a decrease in IMPDH1 expression, colony and invasive cells numbers, and an increase in apoptosis. Guanosine reversed IMPDH1 expression in HCCC-9810 cells, promoting the secretion of inflammatory factors IL-6, IL-8, OPN, VEGF, and VCAM-1 and intensifying epithelial-mesenchymal transition (EMT) progression in the cells. In nude mice, the IMPDH1 inhibitory drug MMF inhibited tumor growth and reduced the expression of tumor stem cell characteristic markers CD133 and SOX2. Guanosine accelerated the malignant progression of ICC inhibition of purine metabolism-related genes, PPAT and IMPDH2, suppressed the malignant phenotype in HCCC-9810 cells, and inhibited tumor growth.

[1]  Qianjin Li,et al.  Arsenic Prodrug-Mediated Tumor Microenvironment Modulation Platform for Synergetic Glioblastoma Therapy. , 2022, ACS applied materials & interfaces.

[2]  Xing-jie Liang,et al.  Membrane‐destabilizing ionizable lipid empowered imaging‐guided siRNA delivery and cancer treatment , 2021, Exploration.

[3]  Xing-jie Liang,et al.  Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer , 2021, Exploration.

[4]  D. Golombek,et al.  Timing of Novel Drug 1A-116 to Circadian Rhythms Improves Therapeutic Effects against Glioblastoma , 2021, Pharmaceutics.

[5]  L. Jie,et al.  GTPBP2 positively regulates the invasion, migration and proliferation of non-small cell lung cancer , 2021, Journal of Cancer.

[6]  Youguo Chen,et al.  Guanosine monophosphate synthase upregulation mediates cervical cancer progression by inhibiting the apoptosis of cervical cancer cells via the Stat3/P53 pathway , 2021, International Journal of Oncology.

[7]  R. Deberardinis,et al.  Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small cell lung cancer. , 2020, The Journal of clinical investigation.

[8]  G. Landman,et al.  IMPDH-Based Cytoophidium Structures as Potential Theranostics in Cancer. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  M. Ávila,et al.  A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma , 2020, Cancers.

[10]  J. R. Peterson,et al.  Freedom of assembly: metabolic enzymes come together , 2020, Molecular biology of the cell.

[11]  B. Shi,et al.  Evaluation of nanomechanical properties of hyperbranched polyglycerols as prospective cell membrane engineering block. , 2020, Colloids and surfaces. B, Biointerfaces.

[12]  J. Kollman,et al.  Cryo-EM structures demonstrate human IMPDH2 filament assembly tunes allosteric regulation , 2020, eLife.

[13]  S. Taylor-Robinson,et al.  Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort. , 2020, Journal of clinical and experimental hepatology.

[14]  P. Rodrigues,et al.  Metabolic rearrangements in primary liver cancers: cause and consequences , 2019, Nature Reviews Gastroenterology & Hepatology.

[15]  Eric P. Smith,et al.  Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story , 2019, Cancers.

[16]  S. Taylor-Robinson,et al.  Characterisation of the Urinary Metabolic Profile of Liver Fluke-Associated Cholangiocarcinoma , 2019, Journal of clinical and experimental hepatology.

[17]  S. Taylor-Robinson,et al.  Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population , 2019, Hepatic medicine : evidence and research.

[18]  Qingmei He,et al.  TRIM21–SERPINB5 aids GMPS repression to protect nasopharyngeal carcinoma cells from radiation-induced apoptosis , 2019, Journal of Biomedical Science.

[19]  J. Revuelta,et al.  A Nucleotide-Dependent Conformational Switch Controls the Polymerization of Human IMP Dehydrogenases to Modulate their Catalytic Activity. , 2019, Journal of molecular biology.

[20]  B. Sangro,et al.  Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis , 2019, Hepatology.

[21]  E. Chan,et al.  Immune Response-Dependent Assembly of IMP Dehydrogenase Filaments , 2018, Front. Immunol..

[22]  J. R. Peterson,et al.  T cell activation triggers reversible inosine-5′-monophosphate dehydrogenase assembly , 2018, Journal of Cell Science.

[23]  R. Deberardinis,et al.  Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. , 2018, Cell metabolism.

[24]  T. Efferth,et al.  Chemoresistance and chemosensitization in cholangiocarcinoma. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[25]  Yoftahe Abebe,et al.  Risk and Surveillance of Cancers in Primary Biliary Tract Disease , 2016, Gastroenterology research and practice.

[26]  Q. Liang,et al.  Serum metabolomics uncovering specific metabolite signatures of intra- and extrahepatic cholangiocarcinoma. , 2016, Molecular bioSystems.

[27]  J. Marin,et al.  Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT). , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[28]  S. Varambally,et al.  Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer , 2015, Oncotarget.

[29]  D. Ruggero,et al.  Protein and Nucleotide Biosynthesis Are Coupled by a Single Rate-Limiting Enzyme, PRPS2, to Drive Cancer , 2014, Cell.

[30]  D. Ruggero,et al.  Protein and Nucleotide Biosynthesis Are Coupled by a Single Rate-Limiting Enzyme, PRPS2, to Drive Cancer , 2014, Cell.

[31]  W. Marsden.  I and J , 2012 .

[32]  K. Zeller,et al.  Global Regulation of Nucleotide Biosynthetic Genes by c-Myc , 2008, PloS one.

[33]  Krister Wennerberg,et al.  The Ras superfamily at a glance , 2005, Journal of Cell Science.

[34]  M. Gautier,et al.  Mapping of the bovine genes of the de novo AMP synthesis pathway. , 2004, Animal genetics.

[35]  H. Koepsell,et al.  Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. , 2002, Molecular pharmacology.

[36]  Kevin Barraclough,et al.  I and i , 2001, BMJ : British Medical Journal.

[37]  F. Collart,et al.  Increased IMP dehydrogenase gene expression in solid tumor tissues and tumor cell lines , 1992 .

[38]  F. Collart,et al.  Increased inosine-5'-phosphate dehydrogenase gene expression in solid tumor tissues and tumor cell lines. , 1992, Cancer research.